<DOC>
	<DOCNO>NCT00088582</DOCNO>
	<brief_summary>5 month study compare SOM230 s.c. Sandostatin s.c. acromegalic patient .</brief_summary>
	<brief_title>Study Comparing SOM230 Subcutaneously Sandostatin Subcutaneously Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Patients active acromegaly due pituitary adenoma Patients previously treat acromegaly certain medication may require without certain medication prior enter study Patients compression optic chiasm cause visual field defect Patients require surgical intervention relief sign symptom associate tumor compression Patients receive radiotherapy 2 year prior start trial Patients congestive heart failure , unstable angina , cardia arrhythmia , history acute myocardial infarction within three month precede enrollment Patients gallstone disease Patients chronic liver disease Known hypersensitivity Sandostatin Sandostatin LAR Female patient pregnant lactating , childbearing potential practicing medically acceptable method birth control highly effective method birth control History immunocompromise , include positive HIV test result Patients history alcohol drug abuse sixmonth period prior enrollment visit Patients participate clinical investigation investigational drug within 4 week prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>SOM230</keyword>
	<keyword>Sandostatin</keyword>
</DOC>